Literature DB >> 17439523

Correlation of amino acid variations within nonstructural 4B protein with initial viral kinetics during interferon-alpha-based therapy in HCV-1b-infected patients.

M-W Welker1, W-P Hofmann, C Welsch, M von Wagner, E Herrmann, T Lengauer, S Zeuzem, C Sarrazin.   

Abstract

Chronic hepatitis C is a major cause of liver cirrhosis leading to chronic liver failure and hepatocellular carcinoma. Different hepatitis C virus (HCV) proteins have been associated with resistance to interferon-alpha-based therapy. However, the exact mechanisms of virus-mediated interferon resistance are not completely understood. The importance of amino acid (aa) variations within the HCV nonstructural (NS)4B protein for replication efficiency and viral decline during the therapy is unknown. We investigated pretreatment sera from 42 patients with known outcome to interferon-based therapy. The complete NS4B gene was amplified and sequenced. Mutational analyses of predicted conformational, functional, structural and phylogenetic properties of the deduced aa sequences were performed. The complete NS4B protein was highly conserved with a median frequency of 0.015 +/- 0.009 aa exchanges (median +/- SD, 4.00 +/- 2.31). Especially within the predicted transmembranous domains of the NS4B protein, the mean number of aa variations was low (median frequency, 0.013 +/- 0.013). Neither the number of aa variations nor specific aa exchanges were correlated with HCV RNA serum concentration at baseline. A rapid initial HCV RNA decline of >/=1.5 log(10) IU/mL at week 2 of interferon-based therapy was associated with a higher frequency of nonconservative aa exchanges within the complete NS4B protein in comparison with patients with a nonrapid HCV RNA decline (median frequency, 0.011 +/- 0.005 vs 0.004 +/- 0.003, P = 0.006). Overall, the aa sequence of the NS4B protein was highly conserved, indicating an important role for replication in vivo. Amino acid variations with relevant changes of physicochemical properties may influence replication efficiency, associated with a rapid early virological response.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17439523     DOI: 10.1111/j.1365-2893.2006.00798.x

Source DB:  PubMed          Journal:  J Viral Hepat        ISSN: 1352-0504            Impact factor:   3.728


  4 in total

1.  The hepatitis C virus NS4B protein can trans-complement viral RNA replication and modulates production of infectious virus.

Authors:  Daniel M Jones; Arvind H Patel; Paul Targett-Adams; John McLauchlan
Journal:  J Virol       Date:  2008-12-10       Impact factor: 5.103

2.  A genetic interaction between hepatitis C virus NS4B and NS3 is important for RNA replication.

Authors:  Anne M Paredes; Keril J Blight
Journal:  J Virol       Date:  2008-08-20       Impact factor: 5.103

3.  High ability to predict the treatment outcome of peginterferon and ribavirin combination therapy based on the reduction in HCV RNA levels at 4 weeks after starting therapy and amino acid substitutions in the hepatitis C virus in patients infected with HCV genotype 1b.

Authors:  Hidenori Toyoda; Takashi Kumada; Seiki Kiriyama; Makoto Tanikawa; Yasuhiro Hisanaga; Akira Kanamori; Toshifumi Tada; Takahiro Arakawa; Masashi Fujimori; Takuro Niinomi; Naoto Ando; Satoshi Yasuda; Keisuke Sakai; Jun Kimura
Journal:  J Gastroenterol       Date:  2010-10-07       Impact factor: 7.527

Review 4.  The role of HCV proteins on treatment outcomes.

Authors:  Kattareeya Kumthip; Niwat Maneekarn
Journal:  Virol J       Date:  2015-12-15       Impact factor: 4.099

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.